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 JCS Advance Online Article. Posted on 26 September 2018
Summary statement 
We demonstrate that cancer related tetraspanin protein CD151 uses novel 
pathways in the regulation of expression of fibroblast growth factor receptor 2 
(FGFR2).  
Abstract  
Expression of the tetraspanin CD151 is frequently upregulated in epithelial 
malignancies and correlates with poor prognosis. Here we report that CD151 
is involved in regulation of the expression of fibroblast growth factor receptor 2 
(FGFR2). Depletion of CD151 in breast cancer cells resulted in an increased 
level of FGFR2. Accordingly, an inverse correlation between CD151 and 
FGFR2 was observed in breast cancer tissues. CD151-dependent regulation 
of the FGFR2 expression relies on post-transcriptional mechanisms involving 
HuR/ELAVL1, a multifunctional RNA binding protein, and the assembly of 
processing bodies (P-bodies). Depletion of CD151 correlated with inhibition of 
PKC a well-established downstream target of CD151. Accordingly, the levels 
of dialcylglycerol species were decreased in CD151-negative cells, and 
inhibition of PKC resulted in the increased expression of FGFR2. Whilst 
expression of FGFR2 itself did not correlate with any of the clinicopathological 
data, the FGFR2-/CD151+ patients are more likely to develop lymph node 
metastasis. Conversely, FGFR2-/CD151- patients demonstrated better overall 
survival. These results illustrate functional interdependency between CD151 
complexes and FGFR2 and suggest a previously unsuspected role of CD151 
in breast tumourigenesis. 
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Introduction  
Tetraspanins represent a large group of four transmembrane domain proteins 
with diverse biological activities (Berditchevski and Rubinstein, 2013). At the 
biochemical level tetraspanins are thought to function as the main structural 
blocks and organisers of distinct microdomains on the plasma membrane 
which also include transmembrane receptors (e.g. integrins, receptor tyrosine 
kinases) and cytoplasmic signalling proteins. Analyses of clinical material 
have suggested that several tetraspanin proteins may be involved in the 
development and metastatic progression in various cancer types (Hemler, 
2014).  
Expression of the tetraspanin CD151 is elevated in various types of breast 
cancer and this correlated with poor prognosis and overall survival in breast 
cancer patients (Kwon et al., 2012; Novitskaya et al., 2014). Experiments 
involving cell lines and animals models suggested that protumourigenic and 
pro-metastatic functions of CD151 are likely to be dependent on its ability to 
form complexes with laminin-binding integrin receptors (i.e. α6β1, α3β1 and 
α6β4) and coordinate integrin-dependent signalling networks in the context of 
receptor tyrosine kinases (Sadej et al., 2014). Specifically, CD151 is known to 
regulate integrin ligand binding and post-adhesion signalling including 
activation of small GTPases (Rho, Rac, cdc42), FAK, cAkt and Erk1/2 (Sadej 
et al., 2014). The association with integrins is also important for CD151--
dependent regulation of cellular responses to growth factors and inhibitory 
drugs that target receptor tyrosine kinases (RTKs) in cancer cells (Deng et al., 
2012; Novitskaya et al., 2014; Sadej et al., 2010). Cross-talk between 
integrins and RTKs was shown to involve classical protein kinase C (PKC), 
well-established molecular partners for several tetraspanin proteins including 
CD151 (Li et al., 2013). In addition to regulating integrin function, CD151 may 
influence the metastatic potential of cancer cells indirectly via E-cadherin–
based cell-cell adhesion complexes (Johnson et al., 2009; Shigeta et al., 
2003), or through the increased production of extracellular matrix degrading 
enzymes (e.g. MMPs) (Hasegawa et al., 2007).  
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 FGFR2 is a member of a receptor tyrosine kinase subfamily which also 
includes FGFR1, FGFR3 and FGFR4 (Kelleher et al., 2013). There is 
increasing evidence that the FGF-FGFR2 signalling axis plays an important 
role in breast cancer. Genome wide analysis has identified a number of single 
nucleotide polymorphic (SNP) variants in intron 2 of the FGFR2 gene which 
were associated with a higher incidence of risk of breast cancer (Cui et al., 
2016), and in particular, in patients positive for hormonal receptors and 
negative for Her2/ErbB2 (Cox et al., 2016). Several transcription factors (e.g. 
FoxA1, Oct1, E2F1) were shown to bind differentially to the high-risk alleles 
and, therefore, might be responsible for elevated expression of FGFR2 in 
patients carrying these alleles (Robbez-Masson et al., 2013). Furthermore, 
gene amplification and overexpression of FGFR2 in breast cancer tissues has 
been also described, particularly in the triple negative (i.e. ER-/PR-/ErbB2-
negative) breast cancers (Turner et al., 2010). Accordingly, overexpression 
and FGFR2 inhibitor studies using human cell models supported the pro--
tumourigenic function of FGFR2 in breast cancer (Bai et al., 2010; Sommer et 
al., 2016). On the other hand, activation of FGFR2 in mouse primary 
mammary epithelial cells resulted in activation of apoptosis (Xian et al., 2007). 
It was also reported that FGFR2 inhibited epithelial-to-mesenchymal transition 
and attenuated growth of human breast cancer xenografts in vivo (Tarkkonen 
et al., 2012).  
Here we describe a new link between tetraspanin CD151 and FGFR2 in 
breast cancer. Specifically, we found that CD151 controls the expression level 
of FGFR2 using a pathway which is independent of proteolytic degradation or 
transcriptional regulation. Instead, it involves the assembly of processing 
bodies (P-bodies) and PKC-dependent signalling pathways. Importantly, the 
inverse correlation between expression of CD151 and FGFR2 in cellular 
models of breast cancer was also observed in breast cancer tissues thus 
emphasizing the importance of our findings for future translational studies. 
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 RESULTS  
CD151 regulates expression of FGFR2 gene. While analysing the 
expression of FGF receptors and tetraspanin proteins in a panel of breast 
cancer cell lines, we noticed a tendency for an inverse correlation between 
the levels of FGFR2 and CD151 (Fig. 1A). In these experiments we detected 
no correlation between expression levels of CD151 and FGFR1 on one hand, 
or between FGFR2 and several other tetraspanins (i.e. CD9, CD63, CD81 
and CD82), on the other (Fig.1A and results are not shown). In agreement 
with this observation stable silencing of CD151 (but not CD63 or CD81) 
resulted in the increased FGFR2 levels in HB2, a DCIS-like mammary 
epithelial cell line, as well as in SKBR3 and MCF7 – two widely used breast 
cancer cell models (Fig. 1B and results are not shown). The re-expression of 
CD151 in HB2/CD151(-) cells reverted the FGFR2 protein level to that 
observed in HB2/CD151(+) cells, thus further excluding the off-target effect of 
the shRNACD151 construct (Fig.1C). An increased level of FGFR2 was also 
observed when CD151 was targeted with an alternative siRNA in transient 
knockdown experiments (Supplementary Fig. 1). Importantly, knockdown of 
CD151 had no effect on expression levels of FGFR1 or FGFR4 (FGFR3 was 
not detectable), emphasizing the specific relationship between CD151 and 
FGFR2 (Fig. 1B).  
Previous studies have demonstrated that most of CD151-dependent 
regulation of cellular function involves laminin-binding integrins ( and 
integrins) (Sadej et al., 2014). Surprisingly, we found that depletion of 
these integrins in HB2 cells, either separately or in combination, had no effect 
on the expression level of FGFR2 (Fig. 1D), thus demonstrating that the 
CD151-dependent regulation of the FGFR2 expression does not involve 
integrins.  
Depletion of CD151 accentuates responses of mammary epithelial 
cells to FGFs. The initial proliferation experiments demonstrated that 
HB2/CD151(+) and HB2/CD151(-) cells responded similarly to FGF2 and 
FGF9 when cultured under standard 2D conditions (Supplementary Fig.2 and 
results are not shown). In contrast, the growth response of CD151-depleted 
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cells to FGFs was more robust when cells were placed in 3D-lrECM (Fig. 2A). 
Furthermore, we noticed that FGF-treated HB2/CD151(-) colonies lost their 
smooth, “ball-like” morphology and appeared as disorganized aggregates of 
cells (Fig. 2A). Importantly, re-expression of the wild type CD151 reversed 
proliferative and morphological phenotypes of HB2/CD151(-) cells (Fig. 2B). 
Similarly, FGF-induced proliferation of CD151–depleted SKBR3 cells in 3D-
lrECM was more pronounced when compared to the control, 
SKBR3/CD151(+) cells (Fig. 2C). Analysis of FGF-triggered signalling of HB2 
cells growing in 3D-lrECM revealed higher levels of phosphorylation of FRS2 
and PLC (specific downstream effectors of FGFR-triggered signalling)in 
CD151-depleted cells (Fig. 2D). Taken together these results demonstrate 
that elevated FGFR2 levels in CD151-depleted cells translate into more 
prominent responses of breast cancer cells to FGFs.   
CD151 regulates expression of FGFR2 at the post-transcriptional level. 
To investigate how CD151 controls the expression of FGFR2 we have initially 
examined the effect of inhibitors of various proteolytic pathways. In these 
experiments we found that treatment of HB2 cells with inhibitors of matrix 
metalloproteases (GM6001, Batimastat), serine proteases (leupeptin), 
aspartic proteases (pepstatin), calpains (calpastatin) and caspases (Z-VAD-
FMK) did not change expression levels of FGFR2 either in CD151-positive or 
CD151-negative cells (Supplementary Fig.3 and not shown). Likewise, 
bafilomycin A1 and MG132, general inhibitors of endosomal/lysosomal and 
proteosomal degradation have no notable effect on FGFR2 levels in 
HB2/CD151(+) and HB2/CD151(-) cells (Supplementary Fig.3 and not 
shown). Therefore, we concluded that CD151-dependent regulation of the 
FGFR2 expression does not involve common proteolytic pathways.  
In further experiments we compared the levels of FGFR2 mRNA in the control 
and CD151-depleted cells. Several probes covering various parts of FGFR2 
mRNA were used in quantitative RT-PCR experiments to account for possible 
variations in FGFR2 splicing. There were no differences observed between 
the control and CD151-depleted cells in these experiments (Supplementary 
Fig.4), thus ruling out the regulation at the level of mRNA.  
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 Transcribed mRNAs bind a diverse range of nuclear proteins which facilitate 
their export to the cytoplasm where the mRNP complexes are either 
immediately translated or stored in various types of cytoplasmic granules 
(Buchan, 2014). Thus, we examined whether depletion of CD151 affected the 
assembly of stress granules (SG), P-bodies and GW bodies, three most 
common types of RNA-containing granules in eukaryotic cells. In these 
experiments we found that the number of P-bodies was noticeably reduced in 
CD151-negative HB2 and SKBr3 cells (Fig. 3A). By contrast, distribution of 
TIA-1 (SG marker) and GW182 (a marker for GW bodies) was comparable in 
HB2/CD151(+) and HB2/CD151(-) (results are not shown). To examine the 
role of P-bodies in FGFR2 expression directly, we have silenced the 
expression of EDC4 and Pat1b, which were shown to regulate the assembly 
of P-bodies. As illustrated in Figure 3B, depletion of either proteins increased 
FGFR2 levels. Therefore, we concluded that the elevated expression of 
FGFR2 in CD151-negative cells is likely to involve P-bodies.   
The mRNA binding protein ELAVL-1/HuR is involved in regulation of 
FGFR2 expression. Nuclear/cytoplasmic proteins TIA-1, TIAR, hnRNP-
C1/C2 and ELAVL-1/HuR were shown to bind FGFR2 mRNA and known to 
be functionally linked to P-bodies. Therefore, we examined whether these 
proteins can be involved in CD151-dependent regulation of expression of 
FGFR2 protein in breast cancer cells. Total expression levels and nuclear vs 
cytoplasmic accumulation of these proteins were comparable in CD151-
positive and CD151-negative cells (Fig. 4A). Knockdown of ELAVL-1/HuR 
resulted in the increased level of FGFR2 protein in HB2 and SKBr3 cells (Fig. 
4B). By contrast, the expression level of FGFR1 was not affected 
(Supplementary Fig.5A). Furthermore, depletion of TIA-1, TIAR or hnRNP-
C1/C2 had no or a minimal effect on the expression levels of FGFR2 in either 
CD151-positive or CD151-negative cells (Supplementary Fig.5B). 
CD151-dependent regulation of FGFR2 expression involves PKC. To 
examine molecular mechanisms that could link CD151 with the activity of 
ELAVL-1/HuR towards FGFR2, we analysed signalling pathways that are 
known to be regulated by tetraspanins, on one hand, and affect the function of 
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ELAVL-1/HuR, on the other. Specifically, we compared activation of Src, p38 
and PKC in the control and CD151-depleted HB2 cells. As illustrated in Figure 
5A the levels of active Src and p38 kinases were comparable in 
HB2/CD151(+) and HB2/CD151(-) cells, thereby ruling out the involvement of 
these proteins in CD151-dependent regulation of FGFR2 expression. CD151 
was shown to associate with classical protein kinases C (cPKC) (Zhang et al., 
2001). Interestingly, we found the phosphorylation levels of several cellular 
proteins recognized by the phospho-(Ser) PKC substrate antibody were 
higher in CD151-positive HB2 cells (Fig. 5B) thus indicating that depletion of 
CD151 resulted in the lower basal level of activation of PKC. Importantly, 
treatment of cells with Bisindolylmaleimide I (BIM I), a highly specific 
PKCinhibitor, increased FGFR2 levels in both HB2 and SKBr3 cells (Fig. 5C). 
Interestingly, treatment of HB2/CD151(+) cells with BIM I had no effect on the 
assembly of P-bodies (Supplementary Fig.6). These results suggest that 
although activation of PKC is important for regulation of FGFR2 expression by 
CD151, other pathways are responsible for the effect of CD151 on the 
assembly of P-bodies. 
It has been previously reported that when activated by PMA/TPA classical 
PKC form complexes with various tetraspanin proteins including CD151 
(Termini and Gillette, 2017). Thus, increased activation of PKC in CD151-
positive breast cancer cells might have been due to the association with 
tetraspanin microdomains (or, more specifically, with CD151-containing 
complexes). However, in accordance to previous studies, PKC was not a part 
of the CD151-complexes purified from cells grown under standard culturing 
conditions (Supplementary Fig.7). We therefore considered whether 
increased PKC activation in CD151-positive cells is due to differences in the 
levels of diacylglycerol (DAG), the physiological activator of classical and 
novel PKC. The quantitative analysis of DAG species in HB2/CD151(+) and 
HB2/CD151(-) cells has revealed that depletion of CD151 resulted in 1.5-2 
fold decrease in the levels of various DAGs species with the most pronounced 
differences observed for 34:1, 36:1, 36:2 and 38:4 species (Fig.5D). 
Importantly, the effect of CD151 depletion on these DAGs was specific as we 
observed no differences in the levels of some other species (e.g. 32:1 and 
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34:2). Although, differences in the levels of DAGs were not due to the activity 
of PLCas monitored by the phosphorylation levels of Tyr783) (Fig.5E), we 
found that depletion of CD151 has resulted in changes in the intracellular 
distribution of the enzyme with most cells losing its prominent PLC-positive 
punca/vesicles (Fig.5F). Thus, we concluded, that CD151-dependent 
regulation of PKC activation and, subsequently, expression of FGFR2 is 
controlled by the abundance of particular DAGs which may be caused by 
changes in compartmentalization of PLC.      
  
Inverse relationship between FGFR2 and CD151 but not FGFR2 alone is 
associated with invasiveness of breast cancer. To examine links between 
FGFR2 and CD151 further, we analysed coexpression of these proteins in 
tissue samples from patients with invasive ductal carcinoma (IDC) (Table 1). 
In the majority of both normal mammary glands and tumours, expression of 
FGFR2 was highly heterogeneous. Various patterns of FGFR2 
immunostaining, i.e. cytoplasmic/membranous (39%; 65/166), nuclear (45%; 
75/166) or ubiquitous (23%; 38/166) could be seen. There was no association 
between levels of FGFR2 immunoreactivity in distinct cellular compartments. 
A highly heterogeneous pattern of immunoreactivity was also observed when 
expression of FGFR2 was analysed in combination with immunoreactivity for 
CD151. Inverse FGFR2/CD151 relationship was seen in 51/166 (31%) and 
38/166 (23%) cases for FGFR2(-)/CD151(+) and FGFR2(+)/CD151(-), 
respectively. In 50/166 cases (30%) tumours were negative for both FGFR2 
and CD151, while a FGFR2(+)/CD151(+) trait was found in minority of 
samples (27/166; 16%). Importantly, Kendall’s test demonstrated a nonlinear 
negative correlation between cytoplasmic/membranous FGFR2 and CD151 
(τ=0.14, p=0.029), thus supporting the inverse relationship between FGFR2 
and CD151 levels in breast cancer cells. Expression of nuclear FGFR2 alone 
did not correlate with any of the tumour characteristics and 
cytoplasmic/membranous FGFR2 was significantly associated only with lack 
of hormone receptors (p=0.04) (Table 1). However, when assessed in 
combination with CD151, an inverse FGFR2/CD151 expression in tumour 
cells was significantly correlated with clinicopathological variables such as 
grade (FGFR2(+)/CD151(-) vs. rest; p=0.012) and nodal status (FGFR2(-
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)/CD151(+) vs rest; p=0.037) (Tables 1 and 2). FGFR2(-)/CD151(+) 
phenotype was also more frequently seen in the triple-negative subgroup of 
the studied cohort (p=0.039) (Table 1). Expression of FGFR2 alone (either 
cytoplasmic/membranous or nuclear) was of no prognostic value (Fig. 6A). 
Interestingly, its absence from the cell, when combined with lack of CD151 
expression (FGFR2(-)/CD151(-)), not only inversely correlated with nodal 
status (p=0.013) and HER2 (p=0.014) (Tables 1 and 2), but also proved a 
good prognostic indicator (p=0.024) (Fig. 6B), albeit not independent (results 
of multivariate analysis not shown).  
 
Discussion  
Dysregulation of the FGF-FGFR2 signalling network is thought to play an 
important role in various epithelial malignancies (Katoh and Nakagama, 
2014). Point mutations, gene amplification, tumour associated alternative 
splicing and gene rearrangements can lead to changes in FGFR2 functions 
(Fearon et al., 2013; Katoh, 2008; Katoh, 2009; Wu et al., 2013). Here we 
show for the first time that the expression of FGFR2 in breast cancer cells is 
controlled by the CD151-based signalling complexes. Importantly, we 
established that CD151-dependent post-transcription regulation of FGFR2 
expression is specific (i.e. CD151 does not regulate expression of FGFR1 or 
FGFR4) and involves PKC.  
Importantly, in agreement with our in vitro observation, an inverse correlation 
between expression of CD151 and FGFR2 was also seen in the tumour 
tissues. These results imply that the pathway(s) which links expression of 
these proteins is(are) also operational in vivo. Expression of FGFR2 alone did 
not have any prognostic value, which confirms our recent observations 
(Czaplinska et al., 2016). Although hormone receptors were the only 
clinicopathological feature associated with FGFR2, in contrast to the previous 
study, its relationship was inverse. The discrepancy between these results 
may reflect differential roles played by FGFR2 in distinct subtypes of breast 
carcinoma, as unlike findings shown by Czaplinska and colleagues, our 
analysis was done on a histologically homogeneous group of specimens (i.e. 
invasive ductal carcinoma). In the patients with inverse correlation of CD151 
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and FGFR2 expression, only those that expressed high levels of CD151 (i.e. 
FGFR2(-)/CD151(+)) demonstrated correlation with lymph node involvement. 
Interestingly, a cohort of FGFR2(+)/CD151(+) patients did not show such 
correlation, which suggests that the presence of FGFR2 may suppress 
prometastatic activity of CD151. Indeed, this and previous studies (Klosek et 
al., 2009; Kwon et al., 2012) revealed a highly significant correlation between 
the expression of CD151 and metastasis to the lymph nodes. Conversely, 
only in the absence of FGFR2 expression, CD151-negative cancer cells 
(FGFR2(-)/CD151(-) cohort) were less likely to be found in the lymph nodes. 
These results suggest that the proposed prometastatic function of CD151 in 
breast and, possibly, other cancers should be assessed in the context of 
FGFR2 expression.  
We discovered that CD151-dependent regulation of FGFR2 expression 
occurs at the posttranscriptional level via the mechanisms involving P-bodies. 
P-bodies are ribonucleoprotein containing cytoplasmic aggregates which are 
known to control mRNA stability and translation (Anderson et al., 2015). The 
involvement of P-bodies adds a new layer of complexity to regulation of 
FGFR2 expression. Our data strongly suggest that HuR/ELAVL-1 is likely to 
be a critical downstream component of the CD151-dependent signalling 
network which is targeting FGFR2 mRNA. In other experiments we found that 
FGFR2 is not the only target for HuR/ELAVL-1 in HB2 cells: expression levels 
of both c-myc and cyclin E, two previously identified targets for HuR/ELAVL-1 
were also increased in HB2/CD151(-) cells (Supplementary Fig.8). These 
results suggest that CD151-dependent regulation of the HuR/ELAVL-1 
function may have wider consequences for CD151-positive breast cancer 
cells.     
HuR/ELAVL-1 is a widely expressed multifunctional RNA binding protein 
which was shown to regulate alternative splicing, mRNA stability and 
translation by binding to AU-rich elements (AREs) in the 3’- and 5’-
untranslated regions of multiple mRNAs (Lebedeva et al., 2011; Uren et al., 
2011). Whilst specific involvement of HuR/ELAVL-1 in regulation of FGFR2 
expression has not been reported previously, the mFGFR2 was identified in 
the transcriptome-wide screen for potential HuR/ELAVL-1 targets (Lebedeva 
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et al., 2011). Furthermore, the recent report by Hubstenberger and colleagues 
demonstrated that HuR/ELAVL-1 and mRNA for FGFR2 segregate to P-
bodies (Hubstenberger et al., 2017). Alternatively, HuR/ELAVL-1 can control 
the expression and/or alternative splicing of various proteins whose function is 
directly linked to the P-body assembly (Lebedeva et al., 2011; Uren et al., 
2011).  
RNA-binding and nuclei-cytoplasm shuttling of HuR/ELAVL-1 are controlled 
by various post-translational modifications of the protein and involve a 
multitude of signalling pathways (Eberhardt et al., 2012; Grammatikakis et al., 
2017). Our data suggest that CD151 regulates the activity of the protein via a 
PKC-dependent signaling pathway. A functional link between CD151 and 
cPKC has been demonstrated in two earlier studies (Li et al., 2013; Shigeta et 
al., 2003). Although not directly examined, both reports suggested that the 
expression of CD151 is correlated with the increased activity of cPKC towards 
their substrates. Using antibodies that detect phosphorylation of PKC 
substrates as our biochemical readout, we demonstrated that the activity of 
PKC is, in fact, suppressed in CD151-depleted cells. This poses an important 
question regarding the nature of the cPKC-CD151 interaction and how the 
removal of the tetraspanin can affect the activity of the enzymes. Previous 
biochemical studies have shown that the interaction between tetraspanins and 
cPKC occurs only under the acute cell stimulation with TPA/PMA (Gustafson-
Wagner and Stipp, 2013; Zhang et al., 2001) or upon activation EGF-/B-cell 
receptors (Deng et al., 2012; Zuidscherwoude et al., 2017). Here we 
demonstrated for the first time that a tetraspanin protein affects PKC-
dependent signalling even under standard/basal growth conditions when the 
association between the proteins is not detected (Suppl Fig.5). This 
observation indicates that the physical link between CD151 and cPKC is not 
necessary for the tetraspanin to modulate the activity of the enzymes towards 
their targets. Rather, it is likely that functionally, CD151 (and, possibly, other 
tetraspanins) are linked to cPKC indirectly. Indeed, we show here for the first 
time that the removal of CD151 in breast cancer cells decreases the 
abundance of particular species of DAG. The importance of this observation is 
that it is not a general change in all DAG rather specific changes in individual 
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molecular species. We have previously discussed the differential regulation of 
signaling by distinct DAG species (Wakelam, 1998). Furthermore, our data 
indicate that the effect of CD151 on the production of DAGs (at least, some of 
the DAG species) may be linked with redistribution of PLC  Thus we propose 
that CD151 affects the activity of PKC by regulating either biosynthetic or 
catabolic pathways linked to the generation of DAGs. Further investigation will 
be necessary to pinpoint how these pathways are directly targeted by the 
tetraspanin.     
In summary, we discovered a novel mechanistic link between the CD151-
complex and FGFR2. The data demonstrate that, in addition to their well 
established role as post-translational regulators of protein expression, 
tetraspanins are also involved in regulation of protein expression at the post-
transcriptional level. Future investigation into molecular pathways responsible 
for tetraspanin/integrin-dependent regulation of FGFR2 expression will further 
define functional interdependence of tetraspanin microdomains and FGFR2 in 
the context of breast cancer. 
MATERIALS AND METHODS  
Cell lines, antibodies and reagents. HB2/CD151(+), HB2/CD151(-), 
HB2/3(-), HB2/6(-), SKBR3/CD151(+), SKBR3/CD151(-), MCF7/CD151(+) 
and MCF7/CD151(-) cells were described previously (Baldwin et al., 2008; 
Novitskaya et al., 2010; Novitskaya et al., 2014). HB2/CD151rec cell line was 
established after transfections of HB2/CD151(−) cells with the construct 
encoding shRNA-resistant form of CD151 (Novitskaya et al., 2014). 
Antibodies to FGFR1 (sc-121), FGFR2 (sc-122), FGFR4 (sc-124), Src (sc-18), 
TIA-1 (sc-1751) were from Santa Cruz. Antibodies to β-actin (A5316) were 
purchased from Sigma-Aldrich; all phospho-specific antibodies (phospho (Ser) 
PKC substrate (#2261), phospho Src Family (Tyr 416) (#2113), phospho p38 
(T180/Y182) (#9215) and phospho-PLCgamma1(Y783)(#2821)) and 
antibodies to EDC4/Ge-1 (#2548), PatL1 (#14288), TIAR (#8509), hnRNP 
C1/C2 (#12392) and HuR/ELAVL-1 (#12582) were from Cell Signaling 
Technologies. All growth factors were purchased from Peprotech; laminin-rich 
extracellular matrix (lrECM) - Matrigel, was from BD Bioscience.  
Culturing of cells in 3D lrECM. Culturing cells in 3D-lrECM was performed 
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as previously described (Sadej et al., 2009). Briefly, 1.5 × 10
3
 cells were 
resuspended in 40l of growth factor reduced lrECM:DMEM (1:1). Solidified lr-
ECM drops were covered with medium containing 2% FBS and 
supplemented, when needed, with FGFs (50 ng/ml). For morphological 
analyses in 3D culture experiments, pictures were taken using a Zeiss 
Primovert microscope coupled with camera (AxioCam ERc 5s, Zeiss). Cell 
proliferation in 3D was measured by WST1 reagent (tetrazolium salts) 
according to the manufacturer’s protocol (Roche). Experiments were 
performed in duplicates, and at least three independent experiments were 
done for each experimental condition. Comparative data were analysed with 
the unpaired Student's t-test using the Statistica 7.1 software. Differences for 
which p<0.05 were considered as statistically significant.  
Western blotting. Cells grown to 80-90% confluence were lysed in Laemmli 
buffer supplemented with 2 mM PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 
5 mM EGTA, 1 mM EDTA, 2 mM Na4P2O7, 5 mM NaF and 5 mM Na3VO4. 
Samples containing equal amounts of protein per lane were loaded and 
resolved on 10% SDS-PAGE and then transferred onto nitrocellulose 
membrane. The membranes were incubated for 1 hour in 5% skimmed milk 
and probed with specific antibodies overnight. The infrared-tagged secondary 
antibodies were used to visualise the signals, and the images were capture 
and quantified using a LI-COR Odyssey scanning system. 
siRNA-based knockdown. Cells were transfected with control or gene-
targeting siRNAs (20 nM) using Lipofectamine®RNAiMAX transfection 
reagent (ThermoFisher). The expression level of FGFR2 was assessed by 
western blotting 72 hours after transfection. For immunofluorescence 
experiments, cells were plated on coverslips the day before transfection and 
analysed 72 hours after transfection. All siRNA were purchased from Qiagen 
in the Flexitube format; target sequences are shown in Supplementary Table1  
Immunofluorescence staining. Cells grown on glass coverslips were fixed 
with 4% paraformaldehyde and permeabilised using 0.1% Triton X-100. 
Staining with rabbit anti-EDC4 Ab (diluted at 1:200) was carried out according 
to the manufacture’s recommendations. P-bodies were quantified in 50-100 
cells in 2-3 independent experiments. For staining using anti- PLC1 antibody 
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(diluted at 1:100, Cell Signaling Technology, #2282) cells were permeabilised 
for 1h in 1%Brij98.  
Real time qPCR. Total RNA was isolated from HB2 cells using the RNAeasy 
kit according to the manufacturer’s instructions (Qiagen, Crawley, United 
Kingdom). The cDNAs were synthesized from RNA (1 g) by MultiScribe™ 
MuLV reverse-transcriptase (Life Technology, Paisley, United Kingdom). Real 
time PCR was carried out using either commercial TaqMan or custom 
designed SYBR Green primers (sequences are available upon request). PCR 
conditions were as follows: (a) 95°C for 10min; (b) 40 cycles of 95°C for 15 s 
and 60°C for 1 min. At least three separate PCR reactions for each gene were 
performed. The real-time amplification data were analysed using REST 
software (Qiagen, Crawley, United Kingdom) and gene expression levels 
were normalized relative to the control GAPDH gene for TaqMan assay or β-
Actin for SYBR green assay. 
Diacylglycerol analysis by mass spectrometry. Frozen cell pellet lipids 
were extracted using the Folch method with Chloroform/Methanol/Water 
(2:1:1 ratio) and resuspended in Chloroform/Methanol (1:1) prior to injection 
into a Shimadzu Prominence 20-AD system (Shimadzu, Kyoto, Japan). 
Chromatographic separation was achieved upon a Waters Acquiity UPLC C4 
(100 x 1 mm, 1.7 µm particle size) column (Milford, MA, U.S.A.). The column 
was kept a 45 °C and 7 µl of samples were eluted using a mobile phase 
composed of solvent A: water and B: acetronitile each containing 0.025 % 
formic acid.  The gradient started at 45 % B (5 min), with an increase to 90 % 
B for 5 min, 100 % B was reached after an additional 10 minutes and held for 
7 min before reequilibration at 45%  B for 5 minutes. The flow rate was 
maintained constant at 100 µL/min. Accurate mass (with an error below 5 
ppm) was acquired on an Orbitrap Elite mass spectrometer (Thermo Fisher 
Scientific, Waltham, MA, USA). Source parameters for positive polarity were: 
capillary temperature 275 °C; source heater temperature 200 °C; sheath gas 
10 AU; aux gas 5 AU; sweep gas 5 AU. Source voltage was 3.8 kV. Full scan 
spectra in the range of m/z 150 to 1,000 were acquired at a target resolution 
of 240,000 (FWHM at m/z 400). Data analysis was performed using Lipid 
Data Analyzer (2.6.0_2) software (Hartler et al., 2017). 
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Patient Selection and Samples are described in Supplementary Table2. 
Specimens of primary invasive ductal carcinoma from women treated in the 
Oncology Department of the Copernicus Memorial Hospital in Lodz, 
Poland between 2003 and 2010 were obtained according to the local ethical 
regulations (License No. RNN/174/11KE, Medical University of Lodz 2011). 
This was an archival material and no consent was  (then) required. 
Immunohistochemistry. Serial m paraffin sections of archival formalin -
fixed blocks were processed for immunohistochemistry for FGFR2 (rabbit anti-
human; 1:100, Santa Cruz, UK) and CD151 (mouse anti-human; 1:100; 
Novocastra, UK) using routine protocols described previously (Novitskaya et 
al., 2014). As a negative control for immunostaining, primary antibodies were 
replaced by nonimmune sera. Scoring immunoreactivity for FGFR2 was 
carried out separately for cytoplasmic/membranous and nuclear FGFR2 
expression. Cytoplasmic/membranous expression of FGFR2 was considered : 
i) 0/negative – if no reactivity, ii) 1+/positive – if weak to moderate 
membranous and/ or cytoplasmic staining in <10% of tumour cells; iii) 
2+/positive – if moderate membranous and/or cytoplasmic staining in ≥10% of 
tumour cells; iv) 3+/positive – if strong membranous and/or cytoplasmic 
staining in ≥ 10% of the tumour cells. Assessment of nuclear immunoreactivity 
was based on Qiuck score (Detre et al., 1995). Scoring of immunoreactivity 
for CD151 was described previously (Novitskaya et al., 2014). 
Immunohistochemical staining was assessed independently by two observers 
(HR and RK) blinded to the clinicopathological data.  
Statistical analysis. Overall survival was calculated from the date of surgery 
to the date of death or the last follow-up, as recommended by the Kaplan-
Meier method. Differences in survival distributions were compared using log-
rank test. Data for patients who died from other causes than breast cancer 
were censored at the time of death. Univariate and multivariate analyses of 
overall survival were performed using the Cox’s proportional 
hazardsregression model. Pearson’s test or Fisher’s exact test were used to 
assess the associations between expression of FGFR2 and CD151 alone and 
their coexpression and clinico-pathological variables. Kendall’s tau rank 
correlation test was used to study correlation between levels of FGFR2 and 
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CD151 expression in cancer tissue. The results were considered statistically 
significant when two-sided p was less than 0.05. The analyses were 
performed using the StatsDirect (StatsDirect Ltd, Altrincham, UK) and 
Statistica 9.1 (StatSoft Inc. Tulsa, OK, USA) software.  
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Tables 
 
 
Table 1. Relationship between clinicopathological features and 
expression of i) FGFR2 alone and ii) in association with CD151. 
Feature  
FGFR2+ 
(n=65) vs. 
rest 
(n=101)  
FGFR2+/CD151-
(n=38) vs. rest 
(n=128)  
FGFR2-/CD151+ 
(n=55) vs. rest 
(n=111)  
FGFR2+/CD151+ 
(n=27) vs. rest 
(n=139)  
FGFR2-/CD151-
(n=50) vs. rest 
(n=116)  
Tumour size  0.131  0.344  0.164  0.487  0.839  
Nodal Status  0.724  0.933  0.037  0.574  0.013  
Stage  0.510  0.366  0.114  >0.999  0.369  
Grade  0.095  0.012  0.102  0.510  0.895  
HER2  0.197  0.771  0.281  0.171  0.014  
ER/PR  0.040  0.221  0.066  0.185  0.736  
TN  0.293  0.595  0.039  0.437  0.333  
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Table 2. Univariate analysis of prognostic factors. 
 
 
 
 
 
 
 
 
 
  
Factor  Hazard Ratio  95%CI  P value  
FGFR2  1.25  0.752.07  0.383  
CD151  1.80  1.083.01  0.023  
FGFR2+/CD151- 0.95  0.521.73  0.87  
FGFR2-/CD151+  1.45  0.872.44  0.16  
FGFR2+/CD151+  1.54  0.842.84  0.17  
FGFR2-/CD151- 0.47  0.240.91  0.024  
Tumour size (T1 vs T24)  1.77  1.302.40  <0.001  
Nodal status  3.01  1.785.10  <0.001  
Stage (I vs II vs III)  1.81  1.272.57  <0.001  
ER/PR  0.53  0.330.87  0.011  
HER2  2.07  1.183.64  0.012  
Grade (G12 vs G3)  1.24  0.762.01  0.383  
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. CD151 regulates expression of FGFR2 gene. A) Inverse 
correlation between CD151 and FGFR2 expression in a panel of breast 
cancer cell lines. Protein lysates (20 g) were resolved in SDS-PAGE and 
expression levels of CD151, CD81 and FGFR2 were analysed by Western 
blotting. Membranes were stained with Ponceau S to control for the amounts 
of loading material. Right panel displays arbitrary density units for FGFR2 and 
CD151 signals. Pearson’s correlation coefficient was calculated using Excel 
2010. B) Knockdown of CD151 in mammary epithelial cells results in a 
specific increase of FGFR2 expression without affecting other FGF receptors. 
Expression of FGF receptors was analysed as described in A. C) Stable re-
expression of shRNA-resistant form of CD151 in CD151-depleted cells 
(HB2/CD151rec) reversed FGFR2 expression in HB2 cells. D) Silencing of  
and  integrins does not affect the expression level of FGFR2.  Expression 
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of FGFR2 was analysed in HB2 cells depleted of CD151 (lane2),  integrin 
subunit (lane 3),  integrin subunit (lane 4) and integrin subunits 
(lane 5). HB2/CD151(+) cells were used as a control. Middle panel shows 
expression levels of and  integrin subunits.   
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Figure 2. CD151 regulates cellular responses to FGFs. HB2 (A,B) and 
SKBR3 (C) CD151(+) vs. CD151(-) cells were embedded in 3D lrECM and 
grown for 8 days in a presence of FGF2 and FGF9 (50 ng/ml). Representative 
images are shown. Proliferation was measured using WST1 reagent as 
described in Material and Methods and shown as histograms in which bars 
represent averaged results (mean) of three independent experiments. Error 
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bars represent SD, p values were calculated using two-tailed t-test and are 
indicated on graphs. Proliferation is presented as percentage of the control, 
CD151-positive cells grown under standard culturing conditions. D) Activation 
of FGFR2-dependent signaling pathways in cells grown under standard 
culturing conditions was analysed by Western blotting. Shown representative 
results of one of three independent experiments.  
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Figure 3. The effect of CD151 depletion on the formation of P-bodies, 
and the role of P-bodies in the expression of FGFR2. A) The number of P-
bodies is decreased in CD151-depleted cells. Cells were grown under 
standard culturing conditions for 48h before staining with the anti-EDC4 
antibody to reveal P-bodies. Shown, representative images. Numbers of P-
bodies was quantified in at least 70-100 cells. Scale bar, 10 μm. On the left 
panel bars represent averaged results (mean) of number of P-bodies per cell. 
Error bars represent SD, p value was calculated using two-tailed t-test. B) 
Knockdown of the key components of P-bodies (EDC4 and PatL1) increases 
FGFR2 expression. Cells were depleted of EDC4 and PatL1 using specific 
siRNAs. The expression of FGFR2 was assessed by Western blotting 72 
hours after transfection. Shown results of one of two independent experiments 
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Figure 4. The role of HuR/ELAVL-1 in CD151-dependent regulation of 
FGFR2 expression. A) Expression levels and distribution of mRNA-binding 
proteins in HB2 cells was analysed by Western blotting using specific 
antibodies. WCL – whole cell lysates; cytopl. and nuclear – cytoplasmic and 
nuclear fractions of the proteins, respectively. Note, HSP90 is only found in 
the cytoplasmic fractions. B) The effect of HuR/ELAVL-1 siRNA knockdown 
on the FGFR2 expression in HB2 and SKBr3 cells. The expression of FGFR2 
was assessed by Western blotting 72 hours after transfection. Shown results 
of one of the two independent experiments. 
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Figure 5. The role of PKC in CD151-dependent regulation of the FGFR2 
expression. A) Activation of p38 and Src in cells grown under standard 
culturing conditions was analysed by Western blotting using appropriate 
phospho specific Abs. Histogram shows compilation of densitometric 
measurements of three independent experiments. R.D.U. – relative density 
units. B) Activation of PKC in cells grown under standard culturing conditions 
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was analysed by Western blotting using phospho-(Ser) PKC substrate 
antibody. C) Cells were grown under standard culturing conditions in the 
presence of BIM-I for 72h and the expression of FGFR2 was assessed by 
Western blotting. Shown a representative image of three independent 
experiments. D) Determination of diacylglycerol species. The concentrations 
of individual DAG molecular species were determined by mass spectrometry 
in HB2/CD151(+) (closed bars) and HB2/CD151(-) cells (open bars) and 
normalized to cellular DNA content. n=4 in each case. E) Activation of PLC 
was assessed by western blotting using anti-phPLC(Tyr783) Ab in 3 
independently prepared cellular lysates. Shown means of ratios signal 
intensities of phPLCtotal-PLC F) Distribution of PLC in HB2/CD151(+) and 
HB2/CD151(-) cells. Cells were grown under standard culturing conditions for 
48h before staining with the anti- PLC antibody. Shown, representative 
images. Scale bar, 10 μm. 
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Figure 6. Kaplan-Meier curves of overall survival for patients with breast 
cancer. A. Patients expressing cytoplasmic/membranous FGFR2 compared 
with FGFR2-negative patients. B. Patients negative for both FGFR2 and 
CD151 (FGFR2(-)CD151(-)) compared with the rest of the cohort.  
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Supplementary Fig.1 
                                          
Transient knockdown of CD151 in HB2 cells resulted in the increased level of 
FGFR2. Note, the correlation between the degree of CD151 knockdown and the 
increase in the expression level of FGFR2.    
  
J. Cell Sci.: doi:10.1242/jcs.220640: Supplementary information
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 S
up
pl
em
en
ta
ry
 in
fo
rm
at
io
n
 Supplementary Fig.2 
                                          
Knockdown of CD151 does not affect proliferative responses of HB2 cells to FGF2. 
Cells were serum starved and subsequently incubated in serum-free growth media 
containing FGF2 (50ng/ml) for indicated time intervals. Number of cells on a given 
day was counted, and ratio to the number of cells plated (“day 0”) was calculated 
and multiplied by 100. Cells were plated in triplicated for each of the time points.      
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Supplementary Fig.3 
                                          
The effect of proteolytic inhibitors on the expression levels of FGFR2 in HB2 cells. 
Cells were incubated with indicated concentrations of the inhibitors for 16 hours and 
the expression of FGFR2 was analysed by Western blotting.      
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Supplementary Fig.4 
                                          
Analysis of the mRNA FGFR2 expression in HB2 cells by RT-qPCR. Top diagram 
shown positions of the amplified regions in the mRNA FGFR2.      
J. Cell Sci.: doi:10.1242/jcs.220640: Supplementary information
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Supplementary Fig.5 
                              
                                                                       
A. Knockdown of HuR/ELAVL-1 does not affect expression of FGFR2. B. 
Knockdown of various RNA binding proteins has no or minimal effect on the FGFR2 
expression in HB2/CD151(+) and  HB2/CD151(-) cells, “CD151(+)” and “CD151(-)” 
respectively. The expression of FGFR2 was assessed by Western blotting 72 hours 
after transfection. 
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Supplementary Fig.6 
                                  
 
Treatment of HB2/CD151(+) cells with a PKC inhibitor has no effect on the assembly 
of P-bodies. Cells were grown under standard culturing conditions in media 
supplemented with BIM I (2) for 72 hours with daily media change. P-bodies were 
visualised with anti-EDC4 Ab. Numbers of P-bodies was quantified in at least 30-50 
cells. Scale bar, 10 μm. 
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Supplementary Fig. 7 
                                          
Cells grown under standard culturing conditions were lysed in 1%Brij98 and CD151-
containing complexes were precipitated using mouse anti-CD151 mAb (5C11). The 
complexes were resolved in SDS-PAGE and the presence of PKC in the complex 
was examined using rabbit anti-PKC Ab. Mouse anti-GFP mAb were used as 
isotype-specific negative control.  
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Supplementary Fig. 8 
                                       
The effect of CD151 knockdown on the expression of cellular proteins that were 
identified as HuR/ELAVL-1 targets.  
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 Supplementary Table 1 
 
gene siRNA sequence 
PatL1 GGACCUUUCUGAACGAGCA 
PatL1 CGUCGACUCUUGCAUCAGA 
  
TIA-1 CGCUCCAAAGAGUACAUAU 
TIA-1 GAUAUUCAUUUGUUCGGUU 
  
TIAL GGAUUUGGAGUAGAUCAAU 
TIAL GUAAACCACCUGCACCUAA 
  
EDC4 GGUGUCUGCACGAGUGGAA 
EDC4 GGAGAUGAUAGCUCCACCU 
  
hnRNPC AACGUCAGCGUGUAUCAGGAA 
hnRNPC UUGGUGAUACCUCAUCCUUGA 
  
ELAVL1/HuR AAGUAGCAGGACACAGCUUGG  
ELAVL1/HuR ACCAGUUUCAAUGGUCAUAAA 
  
6 integrin 
subunit 
GGUCGUGACAUGUGCUCAC 
6 integrin 
subunit 
CAAGACAGCUCAUAUUGAUUU 
  
CD151 CAUGUGGCACCGUUUGCCU 
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Supplementary Table 2.  
 
Patient characteristics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of patients 166 
Age (years) 
     < 50 
     ≥ 50 
 
52 
114 
Disease stage 
    I 
    II 
    III 
 
39 
84 
43 
 
T status 
    T1 
    T2 
    T3 
    T4 
 
55 
103 
1 
7 
Grade 
    1-2 
    3 
 
95 
71 
Nodal status 
   Negative 
   Positive 
 
82 
84 
Steroid receptor status 
   Negative 
   Positive 
 
 
73 
93 
HER2 status 
  Negative 
   Positive 
 
 
138 
28 
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